Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Anticancer Res. 2021 Feb;41(2):1055-1062. doi: 10.21873/anticanres.14862.
BACKGROUND/AIM: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients.
Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups.
The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group.
The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice.
背景/目的：本研究旨在描述接受三氟尿苷/替匹嘧啶（TFTD）和/或瑞戈非尼治疗的结直肠癌（CRC）患者的化疗效果。
选择 2013-2018 年期间接受瑞戈非尼或 TFTD 治疗转移性 CRC 的患者，并将其分为两组：一组在接受瑞戈非尼或 TFTD 后接受额外化疗（CTX 组），另一组未接受额外化疗（非 CTX 组）。患者的随访时间从一个标记点开始（从最后一天接受瑞戈非尼或 TFTD 治疗开始的 90 天）。我们比较了两组之间的总生存期（OS）。
CTX 组的中位 OS 为 7.7 个月，非 CTX 组为 4.1 个月。几项敏感性分析并未否定 CTX 组的生存优势。
瑞戈非尼或 TFTD 后化疗与晚期 CRC 患者的 OS 延长相关。需要进一步研究以确定合适的治疗选择。
